title: The spectrum of statin therapy in cancer patients: is there a need for further investigation?
abstract: Although our understanding of the relationship between cancer and statin use continues to improve, it remains a complex association requiring further research focusing on both biologic and clinical end points in a wide range of patient populations. To date, most of the published results are from observational studies detailing the risk of incident cancers or from randomized controlled trials with cardiovascular primary end points and cancer only as a secondary end point. Although there is certainly great value in the information obtained from observational studies, they cannot prove a causal link between statins and cancer, and it would then seem appropriate to design and implement clinical trials. Such studies should consider three main end products of the mevalonate pathway (cholesterol, geranyl pyrophosphate, and farnesyl pyrophosphate) from a mechanistic perspective, as well as the potential for cancer cell mediation with statin use, in addition to pertinent clinical end points including cancer incidence and mortality.
authors.affiliation: Clinical Professor and Director of Undergraduate Programs, Northeastern University School of Pharmacy, Clinical Pharmacist, Brigham and Women's Hospital, 360 Huntington Ave, Boston, MA, 02115, USA, m.gonyeau@neu.edu.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Gonyeau
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015994:Incidence; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012306:Risk; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors